Literature DB >> 16033970

Mucosal alloimmunization elicits T-cell proliferation, CC chemokines, CCR5 antibodies and inhibition of simian immunodeficiency virus infectivity.

Lesley A Bergmeier1, Kaboutar Babaahmady1, Yufei Wang1, Thomas Lehner1.   

Abstract

The hypothesis was tested that mucosal stimulation with unmatched mononuclear cells would induce systemic alloimmune responses. Rectal or vaginal mucosal administration of 10(4)-10(7) unmatched mononuclear cells induced significant dose-dependent T-cell proliferation stimulated by the allogeneic cells in rhesus macaques. This was associated with a significant upregulation of CD8(+) T-cell-derived suppressor factor, as well as the CC chemokines CCL3, CCL4 and CCL5. In addition, there was a dose-dependent increase in antibodies to CCR5. These responses were associated with decreased in vitro simian immunodeficiency virus (SIV) infectivity of CD4(+) T cells. A further investigation of SIV infectivity of CD4(+) T cells separated from multiparous macaques also showed significant inhibition compared with male macaques. It is suggested that vaginal or rectal exposure to allogeneic stimulation by a partner's HLA antigens in seminal fluid, as occurs during sexual intercourse, or immunization by semi-allogeneic fetuses in multiparous females may elicit protection against SIV or human immunodeficiency virus infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033970     DOI: 10.1099/vir.0.80802-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Working group consultation: alloimmunity as a vaccine approach against HIV/AIDS: National Institutes of Health Meeting Report, May 24, 2012.

Authors:  Anjali Singh; Jon Warren; Alan Schultz; Charles J Hackett; Opendra Sharma
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-23       Impact factor: 2.205

2.  Quantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.

Authors:  Samir K Lakhashe; Madhuri R Thakar; K E Bharucha; Ramesh S Paranjape
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 3.  The role of disease stage, plasma viral load and regulatory T cells (Tregs) on autoantibody production in SIV-infected non-human primates.

Authors:  Aftab A Ansari; Lara E Pereira; Ann E Mayne; Nattawat Onlamoon; Kovit Pattanapanyasat; Kazuyasu Mori; F Villinger
Journal:  J Autoimmun       Date:  2007-03-26       Impact factor: 7.094

4.  Serial cervicovaginal exposures with replication-deficient SIVsm induce higher dendritic cell (pDC) and CD4+ T-cell infiltrates not associated with prevention but a more severe SIVmac251 infection of rhesus macaques.

Authors:  Shaheed A Abdulhaqq; Melween I Martinez; Guobin Kang; Andrea S Foulkes; Idia V Rodriguez; Stephanie M Nichols; Meredith Hunter; Carlos A Sariol; Lynnette A Ruiz; Brian N Ross; Xiangfan Yin; David W Speicher; Ashley T Haase; Preston A Marx; Qinsheng Li; Edmundo N Kraiselburd; Luis J Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

5.  Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.

Authors:  Gene M Shearer; Adriano Boasso
Journal:  F1000 Med Rep       Date:  2011-06-01

Review 6.  Development of a human leukocyte antigen-based HIV vaccine.

Authors:  Yufei Wang
Journal:  F1000Res       Date:  2018-06-22

7.  Heterosexual and homosexual partners practising unprotected sex may develop allogeneic immunity and to a lesser extent tolerance.

Authors:  Cherry Kingsley; Barry Peters; Kaboutar Babaahmady; Laura Pomeroy; Durdana Rahman; Robert Vaughan; Thomas Lehner
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

8.  Greater ethnic diversity correlates with lower HIV prevalence in Africa: justification for an alloimmunity vaccine.

Authors:  Christopher Zamani; Jared D Elzey; James Ek Hildreth
Journal:  HIV AIDS (Auckl)       Date:  2013-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.